| Literature DB >> 27144553 |
Dahong Li1,2,3,4, Tong Han5, Shengtao Xu6, Tingting Zhou7, Kangtao Tian8, Xu Hu9, Keguang Cheng10, Zhanlin Li11, Huiming Hua12, Jinyi Xu13.
Abstract
Isodon rubescens has been used as a traditional green tea for more than 1000 years and many medicinal functions of I. rubescens are also very useful, such as its well-known antitumor and antibacterial activities. Oridonin, a bioactive ent-kaurane diterpenoid, is the major ingredient of this medicinal tea. Herein, 22 novel oridonin derivatives were designed and synthesized. The antibacterial activity was evaluated for the first time. Compound 12 was the most promising one with MIC of 2.0 μg/mL against B. subtilis, which was nearly 3-fold stronger than positive control chloromycetin. The antiproliferative property was also assayed and compound 19 showed stronger activity than taxol. The apoptosis-inducing ability, cell cycle arrest effect at S phase and influence of mitochondrial membrane potential by 19 in CaEs-17 cancer cells were first disclosed. Based on the above results, the cell apoptosis induced by compound 19 in CaEs-17 cells was most probably involved in the intrinsic apoptotic pathway.Entities:
Keywords: Isodon rubescens; diterpenoid; medicinal chemistry; medicinal tea; oridonin
Mesh:
Substances:
Year: 2016 PMID: 27144553 PMCID: PMC6272837 DOI: 10.3390/molecules21050575
Source DB: PubMed Journal: Molecules ISSN: 1420-3049 Impact factor: 4.411
Figure 1Tea drink of the leaves of Isodon rubescens.
Scheme 1Synthetic routine of compounds 2–12 and 14–24.
The antimicrobial activity of oridonin and its derivatives (MIC μg/mL).
| Compound | Clog | ||||
|---|---|---|---|---|---|
| >100 | 31.2 | 31.2 | >100 | −1.70 | |
| >100 | 62.5 | 31.2 | >100 | 0.65 | |
| >100 | 31.2 | 15.6 | >100 | 1.21 | |
| >100 | 15.6 | 3.9 | >100 | 2.35 | |
| >100 | 15.6 | 7.8 | >100 | 1.84 | |
| >100 | 31.2 | 15.6 | >100 | 1.65 | |
| >100 | 31.2 | 15.6 | >100 | 0.91 | |
| >100 | 31.2 | 15.6 | >100 | 0.91 | |
| >100 | 15.6 | 15.6 | >100 | 0.47 | |
| >100 | 62.5 | 31.2 | >100 | 0.76 | |
| >100 | 15.6 | 7.8 | >100 | 1.96 | |
| >100 | 3.9 | 2.0 | >100 | 1.17 | |
| >100 | 62.5 | 31.2 | >100 | −0.06 | |
| >100 | >100 | >100 | >100 | 1.70 | |
| >100 | 62.5 | 31.2 | >100 | 2.26 | |
| >100 | 15.6 | 7.8 | >100 | 3.40 | |
| >100 | 15.6 | 15.6 | >100 | 2.89 | |
| >100 | 62.5 | 15.6 | >100 | 2.70 | |
| >100 | 31.2 | 15.6 | >100 | 1.96 | |
| >100 | 31.2 | 15.6 | >100 | 1.96 | |
| >100 | 31.2 | 15.6 | >100 | 1.52 | |
| >100 | >100 | 62.5 | >100 | 1.81 | |
| >100 | 31.2 | 7.8 | >100 | 3.01 | |
| >100 | 3.9 | 3.9 | >100 | 2.22 | |
| chloromycetin | 3.9 | 3.9 | 7.8 | NT 1 | NT |
| fluconazole | NT | NT | NT | 3.91 | NT |
1 NT, not test; 2 Clog p values were calculated by ChemBioDraw Ultra 12.0 (ChemBridge Corp., San Diego, CA, USA).
Antiproliferative activity of compounds 1–24 against Bel-7402, K562, MGC-803 and CaEs-17 human cancer cells (IC50 μM; mean ± S.D.).
| Compound | Bel-7402 | K562 | MGC-803 | CaEs-17 |
|---|---|---|---|---|
| 7.48 ± 0.53 | 4.76 ± 0.32 | 5.69 ± 0.39 | 11.03 ± 1.02 | |
| 1.18 ± 0.03 | 2.03 ± 0.17 | 1.18 ± 0.21 | 3.36 ± 0.22 | |
| 1.01 ± 0.04 | 1.97 ± 0.18 | 1.12 ± 0.10 | 3.25 ± 0.31 | |
| 0.96 ± 0.06 | 1.83 ± 0.23 | 1.08 ± 0.06 | 3.20 ± 0.29 | |
| 0.97 ± 0.11 | 1.84 ± 0.36 | 1.14 ± 0.23 | 3.16 ± 0.37 | |
| 1.63 ± 0.81 | 0.25 ± 0.02 | 0.81 ± 0.10 | 0.61 ± 0.13 | |
| 1.07 ± 0.52 | 0.31 ± 0.04 | 0.37 ± 0.04 | 0.43 ± 0.10 | |
| 1.13 ± 0.14 | 0.37 ± 0.07 | 0.61 ± 0.01 | 0.28 ± 0.22 | |
| 1.39 ± 0.72 | 0.59 ± 0.19 | 1.03 ± 0.55 | 0.29 ± 0.04 | |
| 3.80 ± 0.92 | 2.66 ± 0.13 | 4.02 ± 0.75 | 7.23 ± 1.03 | |
| 0.90 ± 0.02 | 1.87 ± 0.07 | 1.37 ± 0.09 | 3.92 ± 0.36 | |
| 0.82 ± 0.22 | 1.74 ± 0.23 | 1.12 ± 0.17 | 3.63 ± 0.29 | |
| 2.98 ± 0.14 | 4.34 ± 0.04 | 3.98 ± 0.66 | 7.23 ± 0.73 | |
| 0.98 ± 0.06 | 1.77 ± 0.13 | 1.31 ± 0.14 | 2.72 ± 0.30 | |
| 0.93 ± 0.11 | 1.76 ± 0.24 | 1.08 ± 0.09 | 2.56 ± 0.25 | |
| 0.95 ± 0.07 | 1.81 ± 0.24 | 1.09 ± 0.13 | 3.13 ± 0.22 | |
| 0.99 ± 0.10 | 1.91 ± 0.45 | 1.17 ± 0.15 | 3.46 ± 0.44 | |
| 2.81 ± 0.41 | 0.86 ± 0.03 | 1.02 ± 0.38 | 0.89 ± 0.30 | |
| 0.98 ± 0.05 | 0.29 ± 0.05 | 0.60 ± 0.40 | 0.22 ± 0.09 | |
| 1.66 ± 0.39 | 0.35 ± 0.06 | 0.87 ± 0.05 | 0.64 ± 0.11 | |
| 1.45 ± 0.42 | 0.47 ± 0.01 | 0.90 ± 0.22 | 0.51 ± 0.03 | |
| 3.17 ± 0.65 | 2.16 ± 0.37 | 3.94 ± 0.71 | 8.55 ± 0.80 | |
| 1.07 ± 0.13 | 1.72 ± 0.24 | 1.25 ± 0.16 | 3.62 ± 0.18 | |
| 0.81 ± 0.08 | 1.66 ± 0.26 | 1.09 ± 0.24 | 3.57 ± 0.16 | |
| 1.89 ± 0.09 | 0.41 ± 0.02 | 0.85 ± 0.06 | 0.43 ± 0.03 |
1 Taxol was used a positive control. Data were means ± SD of three experiments.
Figure 2Apoptosis-inducing ability of compound 19 in CaEs-17 cell line.
Figure 3Cell cycle effect on CaEs-17 cells of compound 19.
Figure 4Effect on mitochondrial membrane potential of CaEs-17 cells by compound 19.